WELCOME TO iNANOD
AI-BACKED RAPID TARGETED CANCER CHEMO-IMMUNOTHERAPY
WHAT WE DO
.png)
At iNANOD, we use nanotechnology to make cancer treatment smarter and more effective. Our platform should not just deliver medication more accurately; it is also to stimulate a targeted immune response directly at the tumor site. Based on modern research results, it is our ambition—and we firmly believe it is achievable—to bridge the gap between laboratory innovation and clinical success. By maximizing the power of chemotherapy, nano-biotechnology and empowering the body's natural defences, we are dedicated to creating a lasting impact on global healthcare.
ABOUT
iNANOD AS is a privately owned biotechnology start-up emerging from the Oslo Cancer Cluster Incubator. We leverage nano-biotechnology to develop a next-generation drug delivery platform, with a primary focus on oncology. Our mission is to transform cancer treatment by delivering active pharmaceutical ingredients with high precision and speed while simultaneously activating the immune system. By combining the targeted effects of chemotherapy with advanced immunotherapy, we aim to effectively eliminate solid malignant tumors with minimal side effects.
iNANOD is a high-growth biotech start-up within the prestigious Oslo Cancer Cluster. We use nano-biotechnology to deliver a "double-hit" to solid tumors, combining high-precision faster chemotherapy with immunotherapy. Opportunities to join our mission are becoming limited as we progress toward our next milestones. The window for early-stage partnership is closing fast. Partner with us today before the next phase begins.
THE PEOPLE
BOARD MEMBERS
Åge Nærdal
Chairman
Trained as a Pharmacist having more than 35 years of experience in leadership from pharmaceutical industry.
Stener Kvinnsland
Board member
MD with a PhD in oncology. Various roles in the pharmaceutical an biotech industry, former COB at Oslo University Hospital, former MD of Helse Bergen and former Director at Haukeland University Hospital. Specialist and professor in cancer medicine.
Per Foss
Board member
Bio-organic chemistry doctorate having hugely diverse professional expertise in the industry.
Nalinava Sengupta
Board Member & CEO
After 15 years of academic research in chemistry, turned entrepreneur for a mission.
Thomas Due
Board member
He has over 20 years of Innovation and Venture Capital Fundraising experience in Norway. He has spent most of his adult life working where finance meets entrepreneurs.
SUPPORTERS
MEMBER OF
